;PMID: 9821810
;source_file_628.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..154] = [t:46..154]
;2)section:[e:158..200] = [t:158..200]
;3)section:[e:204..304] = [t:204..304]
;4)sentence:[e:308..468] = [t:308..468]
;5)sentence:[e:469..566] = [t:469..566]
;6)sentence:[e:567..755] = [t:567..755]
;7)sentence:[e:756..1084] = [t:756..1084]
;8)sentence:[e:1085..1264] = [t:1085..1264]
;9)sentence:[e:1265..1389] = [t:1265..1389]
;10)sentence:[e:1391..1569] = [t:1391..1569]
;11)sentence:[e:1570..1760] = [t:1570..1760]
;12)sentence:[e:1762..1952] = [t:1762..1952]
;13)section:[e:1956..2000] = [t:1956..2000]

;section 0 Span:0..40
;Biol Pharm Bull. 1998 Oct;21(10):1062-6.
(SEC
  (FRAG (NNP:[0..4] Biol) (NNP:[5..10] Pharm) (NNP:[11..15] Bull) (.:[15..16] .)
        (CD:[17..21] 1998) (VBD:[22..27] Oct;2) (CD:[27..28] 1)
        (NN:[28..29] -LRB-) (CD:[29..31] 10) (NN:[31..32] -RRB-) (::[32..33] :)
        (CD:[33..36] 106) (CD:[36..39] 2-6) (.:[39..40] .)))

;sentence 1 Span:46..154
;Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit
;juice  components in caco-2 cells.
;[60..71]:substance:"vinblastine"
;[91..105]:substance:"P-glycoprotein"
;[109..125]:substance:"grapefruit juice"
(SENT
  (NP-HLN
    (NP (NN:[46..56] Inhibition))
    (PP (IN:[57..59] of)
      (NP
        (NP (NN:[60..71] vinblastine) (NN:[72..78] efflux))
        (VP (VBN:[79..87] mediated)
          (NP (-NONE-:[87..87] *))
          (PP (IN:[88..90] by)
            (NP-LGS (NN:[91..105] P-glycoprotein))))))
    (PP (IN:[106..108] by)
      (NP
        (NML (NN:[109..119] grapefruit) (NN:[120..125] juice))
        (NNS:[127..137] components)))
    (PP-LOC (IN:[138..140] in)
      (NP (NN:[141..147] caco-2) (NNS:[148..153] cells)))
    (.:[153..154] .)))

;section 2 Span:158..200
;Takanaga H, Ohnishi A, Matsuo H, Sawada Y.
(SEC
  (FRAG (NNP:[158..166] Takanaga) (NNP:[167..169] H,) (NNP:[170..177] Ohnishi)
        (NNP:[178..179] A) (,:[179..180] ,) (NNP:[181..187] Matsuo)
        (NNP:[188..190] H,) (NNP:[191..197] Sawada) (NNP:[198..199] Y)
        (.:[199..200] .)))

;section 3 Span:204..304
;Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Kyushu 
;University, Fukuoka, Japan.
(SEC
  (FRAG (NNP:[204..214] Department) (IN:[215..217] of)
        (NNP:[218..231] Pharmaceutics) (,:[231..232] ,) (NNP:[233..240] Faculty)
        (IN:[241..243] of) (NNP:[244..258] Pharmaceutical)
        (NNPS:[259..267] Sciences) (,:[267..268] ,) (NNP:[269..275] Kyushu)
        (NNP:[277..287] University) (,:[287..288] ,) (NNP:[289..296] Fukuoka)
        (,:[296..297] ,) (NNP:[298..303] Japan) (.:[303..304] .)))

;sentence 4 Span:308..468
;We investigated the effect of components in grapefruit juice (GFJ) on the 
;transport of vinblastine, a substrate of P-glycoprotein (P-gp), across Caco-2
; cells.
;[352..368]:substance:"grapefruit juice"
;[370..373]:substance:"GFJ"
;[396..407]:substance:"vinblastine"
;[411..420]:substance:"substrate"
;[424..438]:substance:"P-glycoprotein"
;[440..444]:substance:"P-gp"
(SENT
  (S
    (NP-SBJ (PRP:[308..310] We))
    (VP (VBD:[311..323] investigated)
      (NP
        (NP (DT:[324..327] the) (NN:[328..334] effect))
        (PP (IN:[335..337] of)
          (NP
            (NP (NNS:[338..348] components))
            (PP-LOC (IN:[349..351] in)
              (NP
                (NP (NN:[352..362] grapefruit) (NN:[363..368] juice))
                (NP (-LRB-:[369..370] -LRB-) (NN:[370..373] GFJ)
                    (-RRB-:[373..374] -RRB-))))))
        (PP (IN:[375..377] on)
          (NP
            (NP (DT:[378..381] the) (NN:[383..392] transport))
            (PP (IN:[393..395] of)
              (NP
                (NP (NN:[396..407] vinblastine))
                (,:[407..408] ,)
                (NP
                  (NP (DT:[409..410] a) (NN:[411..420] substrate))
                  (PP (NN:[421..423] of)
                    (NP
                      (NP (NN:[424..438] P-glycoprotein))
                      (NP (-LRB-:[439..440] -LRB-) (NN:[440..444] P-gp)
                          (-RRB-:[444..445] -RRB-)))))))
            (,:[445..446] ,)
            (PP (IN:[447..453] across)
              (NP (NN:[454..460] Caco-2) (NNS:[462..467] cells)))))))
    (.:[467..468] .)))

;sentence 5 Span:469..566
;The apical to basolateral flux of [3H]vinblastine was increased in the 
;presence of GFJ extracts.
;[503..518]:substance:"[3H]vinblastine"
;[553..556]:substance:"GFJ"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[469..472] The)
        (ADJP (JJ:[473..479] apical)
          (PP (TO:[480..482] to)
            (ADJP (JJ:[483..494] basolateral))))
        (NN:[495..499] flux))
      (PP (IN:[500..502] of)
        (NP (NN:[503..518] -LSB-3H-RSB-vinblastine))))
    (VP (VBD:[519..522] was)
      (VP (VBN:[523..532] increased)
        (NP-2 (-NONE-:[532..532] *))
        (PP-LOC (IN:[533..535] in)
          (NP
            (NP (DT:[536..539] the) (NN:[541..549] presence))
            (PP (IN:[550..552] of)
              (NP (NN:[553..556] GFJ) (NNS:[557..565] extracts)))))))
    (.:[565..566] .)))

;sentence 6 Span:567..755
;The steady-state uptake of [3H]vinblastine from the  apical side was
;significantly increased in the presence of GFJ in a  dose-dependent manner
;within the range of 2.5 to 50% (v/v) of GFJ.
;[594..609]:substance:"[3H]vinblastine"
;[679..682]:substance:"GFJ"
;[731..741]:quantitative-value:"2.5 to 50%"
;[743..746]:quantitative-units:"v/v"
;[751..754]:substance:"GFJ"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[567..570] The) (JJ:[571..583] steady-state)
          (NN:[584..590] uptake))
      (PP (IN:[591..593] of)
        (NP (NN:[594..609] -LSB-3H-RSB-vinblastine)))
      (PP (IN:[610..614] from)
        (NP (DT:[615..618] the) (JJ:[620..626] apical) (NN:[627..631] side))))
    (VP (VBD:[632..635] was)
      (VP
        (ADVP (RB:[636..649] significantly))
        (VBN:[650..659] increased)
        (NP-1 (-NONE-:[659..659] *))
        (PP-LOC (IN:[660..662] in)
          (NP
            (NP (DT:[663..666] the) (NN:[667..675] presence))
            (PP (IN:[676..678] of)
              (NP (NN:[679..682] GFJ)))))
        (PP (IN:[683..685] in)
          (NP
            (NP (DT:[686..687] a)
              (ADJP (NN:[689..693] dose) (HYPH:[693..694] -)
                    (JJ:[694..703] dependent))
              (NN:[704..710] manner))
            (PP (IN:[711..717] within)
              (NP
                (NP (DT:[718..721] the) (NN:[722..727] range))
                (PP (IN:[728..730] of)
                  (NP
                    (NP
                      
                      (QP (CD:[731..734] 2.5) (TO:[735..737] to)
                          (CD:[738..740] 50))
                      (NN:[740..741] %)
                      (PRN (-LRB-:[742..743] -LRB-)
                        (NP
                          (NP (NN:[743..744] v))
                          (PP (SYM:[744..745] /)
                            (NP (NN:[745..746] v))))
                        (-RRB-:[746..747] -RRB-)))
                    (PP (IN:[748..750] of)
                      (NP (NN:[751..754] GFJ)))))))))))
    (.:[754..755] .)))

;sentence 7 Span:756..1084
;Although  naringin and naringenin reduced apical efflux of [3H]vinblastine at
;the  concentration present in GFJ and increased steady-state uptake from the
;apical  side to 124 and 240%, respectively, the observed effect of naringin
;was not  enough to account for the effect of GFJ and naringenin is not
;naturally present  in GFJ.
;[766..774]:substance:"naringin"
;[779..789]:substance:"naringenin"
;[815..830]:substance:"[3H]vinblastine"
;[864..867]:substance:"GFJ"
;[927..930]...[938..939]:quantitative-value:"124"..."%"
;[935..939]:quantitative-value:"240%"
;[978..986]:substance:"naringin"
;[1032..1035]:substance:"GFJ"
;[1040..1050]:substance:"naringenin"
;[1080..1083]:substance:"GFJ"
(SENT
  (S
    (S
      (SBAR-ADV (IN:[756..764] Although)
        (S
          (NP-SBJ (NN:[766..774] naringin) (CC:[775..778] and)
                  (NN:[779..789] naringenin))
          (VP
            (VP (VBD:[790..797] reduced)
              (NP
                (NP (JJ:[798..804] apical) (NN:[805..811] efflux))
                (PP (IN:[812..814] of)
                  (NP (NN:[815..830] -LSB-3H-RSB-vinblastine))))
              (PP-LOC (IN:[831..833] at)
                (NP
                  (NP (DT:[834..837] the) (NN:[839..852] concentration))
                  (ADJP (JJ:[853..860] present)
                    (PP-LOC (IN:[861..863] in)
                      (NP (NN:[864..867] GFJ)))))))
            (CC:[868..871] and)
            (VP (VBD:[872..881] increased)
              (NP
                (NP (JJ:[882..894] steady-state) (NN:[895..901] uptake))
                (PP (IN:[902..906] from)
                  (NP (DT:[907..910] the) (JJ:[911..917] apical)
                      (NN:[919..923] side))))
              (PP (TO:[924..926] to)
                (NP
                  (NP (CD:[927..930] 124)
                    (NML-1 (-NONE-:[930..930] *P*)))
                  (CC:[931..934] and)
                  (NP (CD:[935..938] 240)
                    (NML-1 (NN:[938..939] %)))))
              (,:[939..940] ,)
              (ADVP (RB:[941..953] respectively))))))
      (,:[953..954] ,)
      (NP-SBJ
        (NP (DT:[955..958] the) (VBN:[959..967] observed) (NN:[968..974] effect))
        (PP (IN:[975..977] of)
          (NP (NN:[978..986] naringin))))
      (VP (VBD:[987..990] was) (RB:[991..994] not)
        (ADJP-PRD (JJ:[996..1002] enough)
          (S
            (NP-SBJ (-NONE-:[1002..1002] *))
            (VP (TO:[1003..1005] to)
              (VP (VB:[1006..1013] account)
                (PP-CLR (IN:[1014..1017] for)
                  (NP
                    (NP (DT:[1018..1021] the) (NN:[1022..1028] effect))
                    (PP (IN:[1029..1031] of)
                      (NP (NN:[1032..1035] GFJ)))))))))))
    (CC:[1036..1039] and)
    (S
      (NP-SBJ (NN:[1040..1050] naringenin))
      (VP (VBZ:[1051..1053] is) (RB:[1054..1057] not)
        (ADJP-PRD
          (ADVP (RB:[1058..1067] naturally))
          (JJ:[1068..1075] present))
        (PP-LOC (IN:[1077..1079] in)
          (NP (NN:[1080..1083] GFJ)))))
    (.:[1083..1084] .)))

;sentence 8 Span:1085..1264
;To investigate the effective components in GFJ, we examined the  inhibitory
;effect of several organic solvent extracts of GFJ on the transport of 
;[3H]vinblastine in Caco-2 cells.
;[1128..1131]:substance:"GFJ"
;[1179..1194]:substance:"organic solvent"
;[1207..1210]:substance:"GFJ"
;[1232..1247]:substance:"[3H]vinblastine"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[1085..1085] *))
      (VP (TO:[1085..1087] To)
        (VP (VB:[1088..1099] investigate)
          (NP
            (NP (DT:[1100..1103] the) (JJ:[1104..1113] effective)
                (NNS:[1114..1124] components))
            (PP-LOC (IN:[1125..1127] in)
              (NP (NN:[1128..1131] GFJ)))))))
    (,:[1131..1132] ,)
    (NP-SBJ (PRP:[1133..1135] we))
    (VP (VBD:[1136..1144] examined)
      (NP
        (NP (DT:[1145..1148] the) (JJ:[1150..1160] inhibitory)
            (NN:[1161..1167] effect))
        (PP (IN:[1168..1170] of)
          (NP
            (NP (JJ:[1171..1178] several)
               (JJ:[1179..1186] organic) (NN:[1187..1194] solvent)
              (NNS:[1195..1203] extracts))
            (PP (IN:[1204..1206] of)
              (NP (NN:[1207..1210] GFJ)))))
        (PP (IN:[1211..1213] on)
          (NP
            (NP (DT:[1214..1217] the) (NN:[1218..1227] transport))
            (PP (IN:[1228..1230] of)
              (NP (NN:[1232..1247] -LSB-3H-RSB-vinblastine))))))
      (PP-LOC (IN:[1248..1250] in)
        (NP (NN:[1251..1257] Caco-2) (NNS:[1258..1263] cells))))
    (.:[1263..1264] .)))

;sentence 9 Span:1265..1389
;Organic solvent extracts of GFJ enhanced the  apical to basolateral
;transcellular transport and inhibited the apical efflux.
;[1265..1280]:substance:"Organic solvent"
;[1293..1296]:substance:"GFJ"
(SENT
  (S
    (NP-SBJ
      (NP
         (JJ:[1265..1272] Organic) (NN:[1273..1280] solvent)
        (NNS:[1281..1289] extracts))
      (PP (IN:[1290..1292] of)
        (NP (NN:[1293..1296] GFJ))))
    (VP
      (VP (VBD:[1297..1305] enhanced)
        (NP (DT:[1306..1309] the)
          (ADJP (JJ:[1311..1317] apical)
            (PP (TO:[1318..1320] to)
              (ADJP (JJ:[1321..1332] basolateral))))
          (JJ:[1333..1346] transcellular) (NN:[1347..1356] transport)))
      (CC:[1357..1360] and)
      (VP (VBD:[1361..1370] inhibited)
        (NP (DT:[1371..1374] the) (JJ:[1375..1381] apical)
            (NN:[1382..1388] efflux))))
    (.:[1388..1389] .)))

;sentence 10 Span:1391..1569
;The permeability coefficient of apical to basolateral transport of 
;[3H]vinblastine increased in the order of the ethyl acetate>diethyl 
;ether>methylene chloride extracts of GFJ.
;[1459..1474]:substance:"[3H]vinblastine"
;[1505..1518]:substance:"ethyl acetate"
;[1519..1533]:substance:"diethyl  ether"
;[1534..1552]:substance:"methylene chloride"
;[1565..1568]:substance:"GFJ"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1391..1394] The) (NN:[1395..1407] permeability)
          (NN:[1408..1419] coefficient))
      (PP (IN:[1420..1422] of)
        (NP
          (NP
            (ADJP (JJ:[1423..1429] apical)
              (PP (TO:[1430..1432] to)
                (ADJP (JJ:[1433..1444] basolateral))))
            (NN:[1445..1454] transport))
          (PP (IN:[1455..1457] of)
            (NP (NN:[1459..1474] -LSB-3H-RSB-vinblastine))))))
    (VP (VBD:[1475..1484] increased)
      (PP (IN:[1485..1487] in)
        (NP
          (NP (DT:[1488..1491] the) (NN:[1492..1497] order))
          (PP (IN:[1498..1500] of)
            (NP
              (NP (DT:[1501..1504] the)
                (NML
                  (NML (NN:[1505..1510] ethyl) (NN:[1511..1518] acetate))
                  (PP (SYM:[1518..1519] >)
                    (NP
                      (NP (NN:[1519..1526] diethyl) (NN:[1528..1533] ether))
                      (PP (SYM:[1533..1534] >)
                        (NP (NN:[1534..1543] methylene)
                            (NN:[1544..1552] chloride))))))
                (NNS:[1553..1561] extracts))
              (PP (IN:[1562..1564] of)
                (NP (NN:[1565..1568] GFJ))))))))
    (.:[1568..1569] .)))

;sentence 11 Span:1570..1760
;Since the extracted amount of  naringenin by ethyl acetate was less than that
;with the other organic solvents,  the primary inhibitor in GFJ is suggested
;to be different from this flavonoid.
;[1601..1611]:substance:"naringenin"
;[1615..1628]:substance:"ethyl acetate"
;[1663..1679]:substance:"organic solvents"
;[1694..1703]:substance:"inhibitor"
;[1707..1710]:substance:"GFJ"
;[1750..1759]:substance:"flavonoid"
(SENT
  (S
    (SBAR-ADV (IN:[1570..1575] Since)
      (S
        (NP-SBJ
          (NP (DT:[1576..1579] the) (VBN:[1580..1589] extracted)
              (NN:[1590..1596] amount))
          (PP (IN:[1597..1599] of)
            (NP (NN:[1601..1611] naringenin)))
          (PP-MNR (IN:[1612..1614] by)
            (NP (NN:[1615..1620] ethyl) (NN:[1621..1628] acetate))))
        (VP (VBD:[1629..1632] was)
          (ADJP-PRD
            (ADJP (JJR:[1633..1637] less) (IN:[1638..1642] than))
            (NP
              (NP (DT:[1643..1647] that))
              (PP (IN:[1648..1652] with)
                (NP (DT:[1653..1656] the) (JJ:[1657..1662] other)
                   (JJ:[1663..1670] organic) (NNS:[1671..1679] solvents))))))))
    (,:[1679..1680] ,)
    (NP-SBJ-1
      (NP (DT:[1682..1685] the) (JJ:[1686..1693] primary)
          (NN:[1694..1703] inhibitor))
      (PP-LOC (IN:[1704..1706] in)
        (NP (NN:[1707..1710] GFJ))))
    (VP (VBZ:[1711..1713] is)
      (VP (VBN:[1714..1723] suggested)
        (S
          (NP-SBJ-1 (-NONE-:[1723..1723] *))
          (VP (TO:[1724..1726] to)
            (VP (VB:[1727..1729] be)
              (ADJP-PRD (JJ:[1730..1739] different)
                (PP (IN:[1740..1744] from)
                  (NP (DT:[1745..1749] this) (NN:[1750..1759] flavonoid)))))))))
    (.:[1759..1760] .)))

;sentence 12 Span:1762..1952
;The present study demonstrated the existence of inhibitory components in GFJ
;for  the P-gp function in Caco-2 cells, which are distinct from known
;components such  as naringin or naringenin.
;[1835..1838]:substance:"GFJ"
;[1848..1852]:substance:"P-gp"
;[1929..1937]:substance:"naringin"
;[1941..1951]:substance:"naringenin"
(SENT
  (S
    (NP-SBJ (DT:[1762..1765] The) (JJ:[1766..1773] present)
            (NN:[1774..1779] study))
    (VP (VBD:[1780..1792] demonstrated)
      (NP
        (NP
          (NP (DT:[1793..1796] the) (NN:[1797..1806] existence))
          (PP (IN:[1807..1809] of)
            (NP (JJ:[1810..1820] inhibitory) (NNS:[1821..1831] components)))
          (PP-LOC (IN:[1832..1834] in)
            (NP (NN:[1835..1838] GFJ))))
        (PP (IN:[1839..1842] for)
          (NP (DT:[1844..1847] the) (NN:[1848..1852] P-gp)
              (NN:[1853..1861] function)))
        (PP-LOC (IN:[1862..1864] in)
          (NP
            (NP (NN:[1865..1871] Caco-2) (NNS:[1872..1877] cells))
            (,:[1877..1878] ,)
            (SBAR
              (WHNP-1 (WDT:[1879..1884] which))
              (S
                (NP-SBJ-1 (-NONE-:[1884..1884] *T*))
                (VP (VBP:[1885..1888] are)
                  (ADJP-PRD (JJ:[1889..1897] distinct)
                    (PP (IN:[1898..1902] from)
                      (NP
                        (NP (JJ:[1903..1908] known)
                            (NNS:[1909..1919] components))
                        (PP (JJ:[1920..1924] such) (IN:[1926..1928] as)
                          (NP (NN:[1929..1937] naringin) (CC:[1938..1940] or)
                              (NN:[1941..1951] naringenin)))))))))))))
    (.:[1951..1952] .)))

;section 13 Span:1956..2000
;PMID: 9821810 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1956..1960] PMID) (::[1960..1961] :) (CD:[1962..1969] 9821810)
        (NN:[1970..1971] -LSB-) (NNP:[1971..1977] PubMed) (::[1978..1979] -)
        (NN:[1980..1987] indexed) (IN:[1988..1991] for)
        (NNP:[1992..2000] MEDLINE-RSB-)))
